English
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
Türkçe
简体中文
日本語
한국어
हिन्दी
- Immunocore (NASDAQ:IMCR) said that its cutaneous melanoma candidate brenetafusp was well tolerated and demonstrated durable clinical benefit as both monotherapy and with a PD1 checkpoint inhibitor.
- Among 47 monotherapy patients, the disease control rate was 56% based on 36 with evaluable tumor assessment. Results showed 16 patients in the arm demonstrating stable disease and four with a partial response.
- There were nine patients who received brenetafusp in combination with Merck’s (MRK) Keytruda (pembrolizumab). Of the seven evaluable for efficacy in combination, four achieved disease control.
- Immunocore (IMCR) noted that brenetafusp was well tolerated, with treatment-related adverse events that were manageable and not severe.
- The company is also enrolling patients in a phase 3 trial of brenetafusp in first-line cutaneous melanoma. Patients will be randomized to brenetafusp + Bristol Myers Squibb’s (BMY) Opdivo (nivolumab), Opdivo, or Opdualag (nivolumab and relatlimab).
Read the full article here
